Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Frontiers in oncology（2023）
摘要
eudract.ema.europa.eu/protocol.htm, identifier 2018-004841-17.
更多查看译文
关键词
atezolizumab,cobimetinib,metastatic melanoma,neoadjuvant therapy,vemurafenib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要